Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.200
+0.001 (0.50%)
Apr 29, 2026, 11:20 AM EST
Northwest Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 3.04 | 2.18 | 2.13 | 6.97 | 15.17 | Upgrade
|
| Cash & Short-Term Investments | 3.04 | 2.18 | 2.13 | 6.97 | 15.17 | Upgrade
|
| Cash Growth | 39.77% | 2.31% | -69.48% | -54.08% | 51.95% | Upgrade
|
| Receivables | 0.31 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 2.17 | 1.89 | 2 | 2.46 | 2.12 | Upgrade
|
| Total Current Assets | 5.52 | 4.06 | 4.13 | 9.43 | 17.29 | Upgrade
|
| Property, Plant & Equipment | 21.6 | 20.38 | 21.46 | 19.64 | 19.92 | Upgrade
|
| Goodwill | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | Upgrade
|
| Other Intangible Assets | 53.19 | 1.29 | 1.29 | 1.29 | 1.29 | Upgrade
|
| Other Long-Term Assets | 0.36 | 0.37 | 0.36 | 0.35 | 1.04 | Upgrade
|
| Total Assets | 81.29 | 26.73 | 27.87 | 31.32 | 40.16 | Upgrade
|
| Accounts Payable | 30.82 | 16.97 | 10.24 | 10.69 | 6.98 | Upgrade
|
| Accrued Expenses | - | 4.45 | - | - | - | Upgrade
|
| Short-Term Debt | 9.47 | 14.19 | 3.94 | 15.4 | 7.1 | Upgrade
|
| Current Portion of Long-Term Debt | 32.7 | 20.19 | 16.54 | 0.14 | 0.14 | Upgrade
|
| Current Portion of Leases | 0.37 | 0.33 | 0.31 | 0.35 | 0.32 | Upgrade
|
| Other Current Liabilities | 18.35 | 12.15 | 14.17 | 99.43 | 119.24 | Upgrade
|
| Total Current Liabilities | 91.7 | 68.27 | 45.2 | 126.01 | 133.77 | Upgrade
|
| Long-Term Debt | 17.88 | 28.3 | 20.31 | 5.99 | 25.16 | Upgrade
|
| Long-Term Leases | 4.41 | 4.44 | 4.45 | 4.37 | 5.23 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 13.17 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 1.7 | 4.7 | 4.95 | - | - | Upgrade
|
| Total Liabilities | 128.86 | 105.71 | 74.92 | 136.37 | 164.15 | Upgrade
|
| Common Stock | 1.57 | 1.33 | 1.18 | 1.07 | 0.95 | Upgrade
|
| Additional Paid-In Capital | 1,443 | 1,345 | 1,291 | 1,165 | 1,067 | Upgrade
|
| Retained Earnings | -1,504 | -1,443 | -1,360 | -1,297 | -1,192 | Upgrade
|
| Treasury Stock | -0.01 | - | - | - | - | Upgrade
|
| Comprehensive Income & Other | -1 | 2.96 | 1.46 | 3.07 | 0.28 | Upgrade
|
| Total Common Equity | -60.28 | -94.49 | -65.77 | -128.1 | -123.99 | Upgrade
|
| Shareholders' Equity | -47.57 | -78.98 | -47.06 | -105.04 | -123.99 | Upgrade
|
| Total Liabilities & Equity | 81.29 | 26.73 | 27.87 | 31.32 | 40.16 | Upgrade
|
| Total Debt | 64.83 | 67.44 | 45.56 | 26.25 | 37.94 | Upgrade
|
| Net Cash (Debt) | -61.79 | -65.27 | -43.43 | -19.29 | -22.77 | Upgrade
|
| Net Cash Per Share | -0.04 | -0.05 | -0.04 | -0.02 | -0.02 | Upgrade
|
| Filing Date Shares Outstanding | 1,607 | 1,391 | 1,190 | 1,073 | 960.02 | Upgrade
|
| Total Common Shares Outstanding | 1,567 | 1,329 | 1,176 | 1,068 | 948.45 | Upgrade
|
| Working Capital | -86.18 | -64.21 | -41.08 | -116.58 | -116.48 | Upgrade
|
| Book Value Per Share | -0.04 | -0.07 | -0.06 | -0.12 | -0.13 | Upgrade
|
| Tangible Book Value | -114.09 | -96.41 | -67.69 | -130.02 | -125.91 | Upgrade
|
| Tangible Book Value Per Share | -0.07 | -0.07 | -0.06 | -0.12 | -0.13 | Upgrade
|
| Land | 0.09 | 0.09 | 0.09 | 0.08 | 0.09 | Upgrade
|
| Machinery | 5.92 | 3.69 | 3.26 | 2.54 | 2.11 | Upgrade
|
| Construction In Progress | - | - | - | 2.03 | - | Upgrade
|
| Leasehold Improvements | 19.08 | 17.97 | 17.79 | 13.07 | 13.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.